Hervana Bio
Non-hormonal Female Contraceptive Technology Offering Protection Against STIs
Company Overview
Snapshot
Founded in June 2008 by Rachel Teitelbaum, PhD, Hervana Bio operates with 1–10 employees. The company has secured $1.1 million in total capital across two funding rounds. In December 2012, Hervana Bio received a grant from the Bill & Melinda Gates Foundation.
Business overview
Hervana Bio is a biopharmaceutical company focused on developing women's health products. The company's core technology is a non-hormonal female contraceptive platform, LJ-102, designed to offer protection against sexually transmitted infections while avoiding the drawbacks of current hormone-based methods. Hervana Bio operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals and Drugs Discovery & Development industries, with a focus on consumers in the United States.
Strategic signal
In April 2024, Hervana Bio was highlighted for its development of a non-hormonal contraceptive, marking the first new advancement in this area in 60 years. This signals a significant potential disruption in the women's health market, addressing a long-standing need for alternative contraceptive solutions and indicating strong future growth prospects for the company.
Log in to access full profile ›Company Intelligence Q&A
- What is Hervana Bio's primary focus?
- Hervana Bio is a biopharmaceutical company dedicated to developing women's health products, particularly focusing on non-hormonal female contraceptive technology that also offers protection against sexually transmitted infections.
- When was Hervana Bio founded and by whom?
- Hervana Bio was founded in June 2008 by Rachel Teitelbaum, PhD.
- What significant grant did Hervana Bio receive?
- In December 2012, Hervana Bio received a grant from the Bill & Melinda Gates Foundation for its contraceptive development efforts.
- What is the status of Hervana Bio's product development?
- Hervana Bio's lead product, LJ-102, is currently in the clinical trial stage, aiming to provide a highly effective, long-lasting, and hormone-free contraceptive.
- What was a recent notable mention for Hervana Bio?
- In April 2024, CTech featured Hervana Bio for developing what is described as the first new, non-hormonal contraceptive in 60 years.